prednisone has been researched along with Ph 1 Chromosome in 23 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ponatinib treatment was well tolerated and considered safe with easily manageable side effects." | 5.46 | Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant. ( Bossio, S; De Stefano, L; Gentile, M; Greco, R; Mazzone, C; Morabito, F; Morelli, R; Musolino, C; Palummo, A; Petrungaro, A; Recchia, AG; Uccello, G; Vigna, E, 2017) |
| "Patients with refractory or recurrent acute lymphoblastic leukemia (ALL) were treated with a combination of methotrexate (MTX), vincristine, PEG-asparaginase, and prednisone (MOAP)." | 2.69 | Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia. ( Aguayo, A; Cortes, J; Kantarjian, H; Keating, M; Pierce, S; Thomas, D, 1999) |
| "Among 3,638 children with acute lymphoblastic leukemia (ALL) entered on Pediatric Oncology Group (POG) protocols between June 1981 and April 1989, successful cytogenetic studies were available for 2,519, 58 (2." | 2.67 | Philadelphia chromosome positive childhood acute lymphoblastic leukemia: clinical and cytogenetic characteristics and treatment outcome. A Pediatric Oncology Group study. ( Behm, F; Borowitz, M; Carroll, A; Crist, W; Head, D; Jackson, J; Link, M; Ragab, A; Shuster, J; Steuber, P, 1990) |
| "Among 4,760 acute lymphoblastic leukemia (ALL) patients enrolled from 1986 to 1995 in two subsequent trials of the BFM and AIEOP study group, 61 patients were found to have Philadelphia chromosome-positive (Ph+) ALL." | 2.40 | Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. ( Aricò, M; Bartram, CR; Basso, G; Biondi, A; Conter, V; Gadner, H; Harbott, J; Lampert, F; Masera, G; Reiter, A; Riehm, H; Schrappe, M; Valsecchi, MG; Zimmermann, M, 1998) |
| "Ponatinib treatment was well tolerated and considered safe with easily manageable side effects." | 1.46 | Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant. ( Bossio, S; De Stefano, L; Gentile, M; Greco, R; Mazzone, C; Morabito, F; Morelli, R; Musolino, C; Palummo, A; Petrungaro, A; Recchia, AG; Uccello, G; Vigna, E, 2017) |
| "Philadelphia chromosome positive (Ph(+)) acute lymphoblastic leukemia (ALL) includes at least one-quarter of all adults with ALL." | 1.33 | Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. ( Ottmann, OG; Wassmann, B, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (13.04) | 18.7374 |
| 1990's | 4 (17.39) | 18.2507 |
| 2000's | 4 (17.39) | 29.6817 |
| 2010's | 6 (26.09) | 24.3611 |
| 2020's | 6 (26.09) | 2.80 |
| Authors | Studies |
|---|---|
| Martinelli, G | 1 |
| Papayannidis, C | 1 |
| Piciocchi, A | 1 |
| Robustelli, V | 1 |
| Soverini, S | 1 |
| Terragna, C | 1 |
| Marconi, G | 1 |
| Lemoli, RM | 1 |
| Guolo, F | 1 |
| Fornaro, A | 1 |
| Lunghi, M | 1 |
| de Fabritiis, P | 1 |
| Candoni, A | 1 |
| Selleri, C | 1 |
| Simonetti, F | 1 |
| Bocchia, M | 1 |
| Vitale, A | 1 |
| Frison, L | 1 |
| Tedeschi, A | 1 |
| Cuneo, A | 1 |
| Bonifacio, M | 1 |
| Martelli, MP | 1 |
| D'Ardia, S | 1 |
| Trappolini, S | 1 |
| Tosi, P | 1 |
| Galieni, P | 1 |
| Fabbiano, F | 1 |
| Abbenante, MC | 1 |
| Granier, M | 1 |
| Zhu, Z | 1 |
| Wang, M | 1 |
| Sartor, C | 1 |
| Paolini, S | 1 |
| Cavo, M | 1 |
| Foà, R | 1 |
| Fazi, P | 1 |
| Vignetti, M | 1 |
| Baccarani, M | 1 |
| Zhang, Y | 2 |
| Qian, JJ | 2 |
| Shen, YJ | 1 |
| Hang, SJ | 1 |
| Jin, J | 3 |
| Zhu, HH | 3 |
| Benarous, X | 1 |
| Brocheton, C | 1 |
| Bonnay, C | 1 |
| Boissel, L | 1 |
| Crovetto, C | 1 |
| Lahaye, H | 1 |
| Guilé, JM | 1 |
| Theret, P | 1 |
| Gondry, J | 1 |
| Foulon, A | 1 |
| Kim, E | 1 |
| Yoo, SH | 1 |
| Chen, Z | 1 |
| Sousa, JA | 1 |
| Batista, E | 1 |
| Demeyer, S | 1 |
| Fischer, N | 1 |
| Pellegrino, O | 1 |
| Ribeiro, AS | 1 |
| Martins, LL | 1 |
| Worthy, FR | 1 |
| Goldberg, SD | 1 |
| Ranjitkar, S | 1 |
| Xu, JC | 1 |
| Asmara, AAGY | 1 |
| Karna, MB | 1 |
| Meregawa, PF | 1 |
| Deslivia, MF | 1 |
| Carula, BC | 1 |
| Giostri, GS | 1 |
| Bebber, F | 1 |
| Batista, MFDS | 1 |
| Silva, FBD | 1 |
| Novak, EM | 1 |
| Vilela, JCS | 1 |
| Franco, N | 1 |
| Campos, G | 1 |
| Deligne, LM | 1 |
| Machado, TLA | 1 |
| Degasperi, FA | 1 |
| Scatigna, BF | 1 |
| Falótico, GG | 1 |
| Romero, V | 1 |
| Basile, R | 1 |
| Takata, ET | 1 |
| Kaleka, CC | 1 |
| Debieux, P | 1 |
| Antonioli, E | 1 |
| Zucconi, E | 1 |
| Cohen, M | 1 |
| Ferretti, M | 1 |
| Bampidis, V | 2 |
| Azimonti, G | 2 |
| Bastos, ML | 2 |
| Christensen, H | 2 |
| Fašmon Durjava, M | 2 |
| Kouba, M | 2 |
| López-Alonso, M | 2 |
| López Puente, S | 2 |
| Marcon, F | 2 |
| Mayo, B | 2 |
| Pechová, A | 2 |
| Petkova, M | 2 |
| Ramos, F | 2 |
| Sanz, Y | 2 |
| Villa, RE | 2 |
| Woutersen, R | 2 |
| Brantom, P | 2 |
| Chesson, A | 2 |
| Westendorf, J | 2 |
| Manini, P | 2 |
| Pizzo, F | 2 |
| Dusemund, B | 2 |
| Aron, J | 1 |
| Albert, PS | 1 |
| Gribble, MO | 1 |
| Samankul, A | 1 |
| Senawong, G | 1 |
| Swatsitang, P | 1 |
| Sripa, B | 1 |
| Phaosiri, C | 1 |
| Kanokmedhakul, S | 1 |
| Senawong, T | 1 |
| Sirajudeen, MS | 1 |
| Alzhrani, M | 1 |
| Alanazi, A | 1 |
| Alqahtani, M | 1 |
| Waly, M | 1 |
| Unnikrishnan, R | 1 |
| Muthusamy, H | 1 |
| Alrubaia, W | 1 |
| Alanazi, N | 1 |
| Seyam, MK | 1 |
| Kashoo, F | 1 |
| Miraj, M | 1 |
| Channmgere Govindappa, S | 1 |
| Alghamdi, KA | 1 |
| Al-Hussinan, NM | 1 |
| Wang, Z | 2 |
| Qu, T | 1 |
| Qi, H | 1 |
| Zhao, S | 1 |
| Shi, H | 2 |
| Bai, W | 1 |
| Yu, Y | 1 |
| Wu, X | 1 |
| Zhao, P | 1 |
| Yakubov, S | 1 |
| Stockerl, WJ | 1 |
| Tian, X | 1 |
| Shahin, A | 1 |
| Mandigma, MJP | 1 |
| Gschwind, RM | 1 |
| Barham, JP | 1 |
| Li, R | 1 |
| Jiang, D | 1 |
| Du, P | 1 |
| Yuan, C | 1 |
| Cui, X | 1 |
| Tang, Q | 1 |
| Zheng, J | 1 |
| Li, Y | 1 |
| Lu, K | 1 |
| Ren, X | 1 |
| Gao, S | 1 |
| Zhan, X | 1 |
| Ramgoolam, KH | 1 |
| Dolphin, AC | 1 |
| Shi, Q | 1 |
| Zhou, YJ | 1 |
| Fang, JG | 1 |
| Zhong, X | 1 |
| Chen, LZ | 1 |
| Hou, HZ | 1 |
| Ma, L | 1 |
| Feng, SZ | 1 |
| He, JW | 1 |
| Huang, R | 1 |
| Wang, YF | 1 |
| Yang, Y | 1 |
| Guo, FL | 1 |
| Li, LJ | 2 |
| Ruan, XH | 2 |
| Fu, GM | 1 |
| Zhao, JZ | 2 |
| Hou, XK | 1 |
| Gao, M | 2 |
| Zheng, XQ | 2 |
| Zeng, Y | 1 |
| Huang, DM | 1 |
| Zhang, JM | 1 |
| Zhang, H | 1 |
| Kang, M | 1 |
| Zhu, J | 1 |
| Xu, YJ | 1 |
| Li, SN | 1 |
| Lai, JM | 1 |
| Liu, JJ | 1 |
| Wen, S | 2 |
| Yan, HH | 1 |
| Cheng, R | 1 |
| Zhu, F | 1 |
| Gao, PF | 1 |
| Zou, HY | 1 |
| Huang, CZ | 1 |
| Wang, J | 2 |
| AbdElgawad, H | 1 |
| Zinta, G | 1 |
| Hornbacher, J | 1 |
| Papenbrock, J | 1 |
| Markakis, MN | 1 |
| Asard, H | 1 |
| Beemster, GTS | 1 |
| Fukushi, Y | 1 |
| Akamine, Y | 1 |
| Abumiya, M | 1 |
| Tozawa, N | 1 |
| Yamashita, T | 1 |
| Nara, M | 1 |
| Kameoka, Y | 1 |
| Takahashi, N | 1 |
| Miura, M | 1 |
| Qi, G | 1 |
| Yu, T | 1 |
| Li, J | 1 |
| Guo, Z | 1 |
| Ma, K | 1 |
| Jin, Y | 1 |
| Lucon-Xiccato, T | 1 |
| Montalbano, G | 1 |
| Gatto, E | 1 |
| Frigato, E | 1 |
| D'Aniello, S | 1 |
| Bertolucci, C | 1 |
| Shi, W | 1 |
| Ge, N | 1 |
| Yu, S | 1 |
| Wu, J | 1 |
| Hu, T | 1 |
| Wei, J | 2 |
| Yan, X | 1 |
| Wang, X | 1 |
| Lin, K | 1 |
| Deng, T | 1 |
| Qu, H | 1 |
| Ou, H | 1 |
| Huang, Q | 1 |
| Gao, B | 1 |
| Li, X | 2 |
| Wei, N | 1 |
| von Haeften, K | 1 |
| Laarmann, T | 1 |
| Wabnitz, H | 1 |
| Möller, T | 1 |
| Gries, KJ | 1 |
| Hart, CR | 1 |
| Kunz, HE | 1 |
| Ryan, Z | 1 |
| Zhang, X | 1 |
| Parvizi, M | 1 |
| Liu, Y | 1 |
| Dasari, S | 1 |
| Lanza, IR | 1 |
| Perez, HL | 1 |
| Andonian, C | 1 |
| Wan, KX | 1 |
| Potts, D | 1 |
| Gonzalez, P | 1 |
| Smith, I | 1 |
| Kavetska, O | 1 |
| Xie, M | 1 |
| Lu, Y | 1 |
| Ouyang, G | 1 |
| Shi, T | 1 |
| Yang, M | 2 |
| Le, J | 1 |
| Hu, H | 1 |
| Zhang, L | 2 |
| Feng, W | 1 |
| Meng, H | 1 |
| Mai, W | 1 |
| Qian, J | 1 |
| Xu, G | 1 |
| Yang, C | 1 |
| Lin, Y | 1 |
| Qian, S | 1 |
| Kuang, Y | 1 |
| Zhu, W | 1 |
| Yao, G | 1 |
| Wu, G | 1 |
| Hu, S | 1 |
| Huang, X | 2 |
| Wang, Y | 1 |
| Tong, H | 1 |
| Haddad, FG | 1 |
| Kourie, HR | 1 |
| Saleh, K | 1 |
| Li, XY | 1 |
| Wang, SS | 1 |
| Meng, HT | 1 |
| Yu, WJ | 1 |
| Tong, HY | 1 |
| Ye, XJ | 1 |
| Petrungaro, A | 1 |
| Gentile, M | 1 |
| Mazzone, C | 1 |
| Greco, R | 1 |
| Uccello, G | 1 |
| Recchia, AG | 1 |
| De Stefano, L | 1 |
| Bossio, S | 1 |
| Palummo, A | 1 |
| Morelli, R | 1 |
| Musolino, C | 1 |
| Morabito, F | 1 |
| Vigna, E | 1 |
| Sciumè, M | 1 |
| Fracchiolla, NS | 1 |
| Cortelezzi, A | 1 |
| Perol, L | 1 |
| Grignano, E | 1 |
| Contejean, A | 1 |
| Gastaud, L | 1 |
| Legoff, M | 1 |
| Franchi, P | 1 |
| Deau-Fischer, B | 1 |
| Willems, L | 1 |
| Bouscary, D | 1 |
| Tamburini, J | 1 |
| Ravandi, F | 1 |
| Jorgensen, JL | 1 |
| Thomas, DA | 1 |
| O'Brien, S | 1 |
| Garris, R | 1 |
| Faderl, S | 1 |
| Burger, JA | 1 |
| Ferrajoli, A | 1 |
| Kebriaei, P | 1 |
| Champlin, RE | 1 |
| Estrov, Z | 1 |
| Challagundla, P | 1 |
| Wang, SA | 1 |
| Luthra, R | 1 |
| Cortes, JE | 1 |
| Kantarjian, HM | 3 |
| Toft, N | 1 |
| Birgens, H | 1 |
| Abrahamsson, J | 1 |
| Griškevičius, L | 1 |
| Hallböök, H | 1 |
| Heyman, M | 1 |
| Klausen, TW | 1 |
| Jónsson, ÓG | 1 |
| Palk, K | 1 |
| Pruunsild, K | 1 |
| Quist-Paulsen, P | 1 |
| Vaitkeviciene, G | 1 |
| Vettenranta, K | 1 |
| Asberg, A | 1 |
| Helt, LR | 1 |
| Frandsen, T | 1 |
| Schmiegelow, K | 1 |
| Ding, J | 1 |
| Bao, W | 1 |
| Zhao, G | 1 |
| Chen, J | 1 |
| Song, H | 1 |
| Kneller, A | 1 |
| Cohen, N | 1 |
| Berkowicz, M | 1 |
| Reichart, M | 1 |
| Rosner, E | 1 |
| Sokolovski, M | 1 |
| Nagler, A | 1 |
| Rechavi, G | 1 |
| Amariglio, N | 1 |
| Trakhtenbrot, L | 1 |
| Ottmann, OG | 1 |
| Wassmann, B | 1 |
| Abla, O | 1 |
| Gassas, A | 1 |
| Stevens, R | 1 |
| Grant, R | 1 |
| Abdelhaleem, M | 1 |
| Schrappe, M | 1 |
| Aricò, M | 1 |
| Harbott, J | 1 |
| Biondi, A | 1 |
| Zimmermann, M | 1 |
| Conter, V | 1 |
| Reiter, A | 1 |
| Valsecchi, MG | 1 |
| Gadner, H | 1 |
| Basso, G | 1 |
| Bartram, CR | 1 |
| Lampert, F | 1 |
| Riehm, H | 1 |
| Masera, G | 1 |
| Aguayo, A | 1 |
| Cortes, J | 1 |
| Thomas, D | 1 |
| Pierce, S | 1 |
| Keating, M | 1 |
| Kantarjian, H | 1 |
| Garcia-Manero, G | 1 |
| Xue, YQ | 1 |
| Guo, Y | 1 |
| Lu, DR | 1 |
| Gu, J | 1 |
| Lu, DW | 1 |
| Gong, JX | 1 |
| Wang, MH | 1 |
| Zhu, WY | 1 |
| Lin, BJ | 1 |
| Crist, W | 1 |
| Carroll, A | 1 |
| Shuster, J | 1 |
| Jackson, J | 1 |
| Head, D | 1 |
| Borowitz, M | 1 |
| Behm, F | 1 |
| Link, M | 1 |
| Steuber, P | 1 |
| Ragab, A | 1 |
| McGlave, P | 1 |
| Arthur, D | 1 |
| Haake, R | 1 |
| Hurd, D | 1 |
| Miller, W | 1 |
| Vercellotti, G | 1 |
| Weisdorf, D | 1 |
| Kim, T | 1 |
| Ramsay, N | 1 |
| Kersey, J | 1 |
| Cervantes, F | 1 |
| Rozman, C | 1 |
| Ballesta, F | 1 |
| Milá, M | 1 |
| Smith, TL | 1 |
| McCredie, KB | 1 |
| Keating, MJ | 1 |
| Walters, RS | 1 |
| Talpaz, M | 1 |
| Hester, JP | 1 |
| Bligham, G | 1 |
| Gehan, E | 1 |
| Freireich, EJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Front-line Treatment of Philadelphia Positive/BCR-ABL Positive Acute Lymphoblastic Leukemia With Ponatinib, a New Potent Tyrosine Kinase Inhibitor.[NCT01641107] | Phase 2 | 44 participants (Actual) | Interventional | 2014-12-04 | Completed | ||
| Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph-positive Acute Lymphoblastic Leukemia[NCT04554459] | Phase 2 | 32 participants (Anticipated) | Interventional | 2021-02-16 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for prednisone and Ph 1 Chromosome
| Article | Year |
|---|---|
Topics: Acceptance and Commitment Therapy; Adolescent; Adult; Aged; Aldehydes; Alpinia; Animals; Antibodies, | 2023 |
Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Child; | 1998 |
The hyper-CVAD regimen in adult acute lymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Antibodies, Monoclonal; Anti | 2000 |
4 trials available for prednisone and Ph 1 Chromosome
| Article | Year |
|---|---|
Topics: Acceptance and Commitment Therapy; Adolescent; Adult; Aged; Aldehydes; Alpinia; Animals; Antibodies, | 2023 |
Dasatinib plus prednisone as induction and consolidation for adults with Ph-positive acute lymphoblastic leukaemia: A single-arm, multicentre, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Disease-Free Survival; Hemat | 2023 |
Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Drug Administration Sched | 1999 |
Philadelphia chromosome positive childhood acute lymphoblastic leukemia: clinical and cytogenetic characteristics and treatment outcome. A Pediatric Oncology Group study.
Topics: Asparaginase; Child; Child, Preschool; Cohort Studies; Cross-Sectional Studies; Female; Humans; Immu | 1990 |
17 other studies available for prednisone and Ph 1 Chromosome
| Article | Year |
|---|---|
INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Imidazoles; Phi | 2022 |
The first report of complete remission following treatment with venetoclax plus prednisone in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Topics: Aged; Bridged Bicyclo Compounds, Heterocyclic; Hematopoietic Stem Cell Transplantation; Humans; Phil | 2022 |
Moving away from chemotherapy in newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Humans; Philadelphia Chromosome; P | 2023 |
An oral, chemotherapy-free regimen (dasatinib plus prednisone) as induction and consolidation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Conso | 2020 |
Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant.
Topics: Adenine Nucleotides; Adult; Arabinonucleosides; Bone Marrow; Clofarabine; Cyclophosphamide; Disease- | 2017 |
Severe hypofibrinogenemia associated with imatinib and prednisone therapy in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adult; Afibrinogenemia; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fibrinogen; Hu | 2018 |
High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Cyclophosphamide; Dose-Res | 2019 |
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclopho | 2013 |
Toxicity profile and treatment delays in NOPHO ALL2008-comparing adults and children with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; | 2016 |
Effect of splenectomy on pancytopenia after a peripheral blood stem cell transplantation.
Topics: Adult; Busulfan; Cyclophosphamide; Dexamethasone; Female; Graft Survival; Graft vs Host Disease; Hem | 2011 |
Acquisition of a Ph chromosome with minor BCR/ABL fusion in treatment-related myelodysplastic syndrome with chromosome 7 abnormalities in a patient treated for Hodgkin disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chromosome Aberrations; Chromosome | 2005 |
Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; C | 2005 |
bcr-abl-positive T-cell acute lymphoblastic leukemia associated with parvovirus B19 infection.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Cerebral Hemo | 2006 |
A case of basophilic leukemia bearing simultaneous translocations t(8;21) and t(9;22).
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 21; Chromosomes, Human, Pai | 1991 |
Therapy of chronic myelogenous leukemia with allogeneic bone marrow transplantation.
Topics: Antigens, Surface; Antilymphocyte Serum; Bone Marrow Transplantation; Cyclophosphamide; Graft vs Hos | 1987 |
[Cytogenetic and therapeutic results of a protocol including splenectomy and intensive polychemotherapy in Ph'-positive chronic myeloid leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Clone Cells; Combined Modality Therapy; Cy | 1986 |
Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Basophils; Blood Cell Coun | 1985 |